CLAIMS

1. A method of treatment of non-alcoholic steatohepatitis (NASH) comprising administration of semaglutide to a subject.

2. The method according claim 1, wherein said subject further has liver fibrosis stage 1-3 according to the Kleiner fibrosis classification.

3. The method according to claim 1, wherein said subject further has liver fibrosis stage 2 or 3 according to the Kleiner fibrosis classification.

4. The method according to any one of the preceding claims, wherein said method is for chronic management of NASH.

5. The method according to any one of the preceding claims, wherein said semaglutide is the sole active ingredient or the sole GLP-1 receptor agonist administered to said subject.

6. The method according to any one of the preceding claims, wherein said semaglutide is administered by subcutaneous administration.

7. The method according to any one of the preceding claims, wherein said semaglutide is administered in an amount in the range of about 0.7 to about 5 mg per week.

8. The method according to any one of the preceding claims, wherein said semaglutide is administered in an amount in the range of about 2.0 to about 3.5 mg per week.

9. The method according to any one of the preceding claims, wherein said semaglutide is administered in an amount in of about 2.4 mg per week.

10. The method according to any one of the preceding claims, wherein said semaglutide is administered in an amount in of about 2.8 mg per week.

11. The method according to any one of the preceding claims, wherein said semaglutide is administered once daily or less frequent.

12. The method according to claim 11, wherein said semaglutide is administered once weekly.

13. The method according to any one of the preceding claims, wherein said method provides no worsening of liver fibrosis in said subject.

14. The method according to any one of the preceding claims, wherein said semaglutide is administered in the form of a pharmaceutical composition in the form of an aqueous solution comprising one or more pharmaceutically acceptable excipients.

15. The method according to claim 14, wherein said pharmaceutical composition is an aqueous solution comprising about 1.0 mg/ml semaglutide, about 1.42 mg/ml disodium hydrogen phosphate dihydrate, about 14.0 mg/ml propylene glycol, about 5.50 mg/ml phenol at about pH 7.4.